BRAINSTORM CELL THERAPEUTICS INC.
brainstorm-cell.comAI Executive Summary
AI-powered analysis of 10-K filing content
BrainStorm Cell Therapeutics faces severe financial and regulatory challenges with FDA rejection of their primary ALS treatment, ongoing losses, delisting from NASDAQ, and substantial going concern doubts. The company shows declining R&D spending, reduced general expenses suggesting cost-cutting measures, and material weaknesses in financial controls while having no revenue generation since inception in 2000.
Red Flags Detected (8)
FDA refused to file BLA for NurOwn ALS treatment in November 2022
Advisory Committee voted against approval on September 27, 2023
Common stock delisted from NASDAQ, now trading on OTCQB
5 more red flags detected
Key Takeaways
Core ALS treatment failed to gain FDA approval despite File over Protest request
Company forced to cut costs with R&D spending down $476K and G&A down $1.3M
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.